Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial [0.03%]
利拉鲁肽对心血管高危超重和肥胖成人内脏脂肪和异位脂肪的影响：随机双盲安慰剂对照试验
Ian J Neeland,Steven P Marso,Colby R Ayers et al.
Ian J Neeland et al.
Background: Visceral and ectopic fat are key drivers of adverse cardiometabolic outcomes in obesity. We aimed to evaluate the effects of injectable liraglutide 3·0 mg daily on body fat distribution in adults with overwei...
Kishore M Gadde,Steven B Heymsfield
Kishore M Gadde
Bart O Roep,Enrique Montero,René van Tienhoven et al.
Bart O Roep et al.
Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group [0.03%]
儿童、青少年和青年癌症幸存者的骨密度监测：国际儿童癌症后遗症指南协调小组的基于证据的推荐意见
Jenneke E van Atteveld,Renée L Mulder,Marry M van den Heuvel-Eibrink et al.
Jenneke E van Atteveld et al.
Childhood, adolescent, and young adult cancer survivors are at increased risk of reduced bone mineral density. Clinical practice surveillance guidelines are important for timely diagnosis and treatment of these survivors, which could improv...
Shahrad Taheri,Mohammed Al-Thani
Shahrad Taheri
Scientific medical conferences can be easily modified to improve female inclusion: a prospective study [0.03%]
科学医学会议可以轻松修改以提高女性参与度：一项前瞻性研究
Victoria Salem,Jordan McDonagh,Elizabeth Avis et al.
Victoria Salem et al.
Long-term population-based trends in the incidence of cardiovascular disease in individuals with type 1 diabetes from Finland: a retrospective, nationwide, cohort study [0.03%]
芬兰1型糖尿病患者心血管疾病发病率的长期人口趋势：一项回顾性全国队列研究
Valma Harjutsalo,Drazenka Pongrac Barlovic,Per-Henrik Groop
Valma Harjutsalo
Background: Cardiovascular disease is the main determinant of premature mortality in patients with type 1 diabetes. However, time trends regarding different types of cardiovascular disease in childhood-onset type 1 diabet...
Trevor J Orchard
Trevor J Orchard
Xavier Rossello,Francisca Caimari
Xavier Rossello
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial [0.03%]
具有心血管代謝風險因素的COVID-19住院患者的達格列凈治療（DARE-19）：一項随机、雙盲、安慰劑對照的III期臨床試驗
Mikhail N Kosiborod,Russell Esterline,Remo H M Furtado et al.
Mikhail N Kosiborod et al.
Background: COVID-19 can lead to multiorgan failure. Dapagliflozin, a SGLT2 inhibitor, has significant protective benefits for the heart and kidney. We aimed to see whether this agent might provide organ protection in pat...